ReviewCancer metastasis reviews2025
Lymphatic metastasis in pancreatic cancer: from bedside to bench and back.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Post-Pancreatectomy Acute Pancreatitis in Pancreatic Cancer: A Single-Center Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma.Biomarker research · 2026Article
- Low prealbumin predicts early recurrence after pancreatic cancer surgery: a retrospective cohort study.Gland surgery · 2026Article
- Explainable multi-omics modeling for risk stratification in pancreatic ductal adenocarcinoma.Gland surgery · 2026Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic cancer is an extremely aggressive and lethal malignant cancer; almost half of the patients have distant metastasis when first diagnosed, and many challenges arise during treatment. Lymph node metastasis is a vital indicator of disease progression in pancreatic cancer and directly influences patient prognosis and survival rate. The cancer cells invade the lymphatics, promote the growth of lymphatics, propagate to lymph nodes, and finally settle down in lymph nodes. Aiming at this process, treatment modalities involving surgery, targeted therapy, and nanodelivery of chemotherapy are tested regarding their efficacy in both local tumor management and lymph node metastasis. As lymph node metastasis presents a poor prognosis and higher recurrence rate, precise assessment of lymph node metastasis is imperative for clinical management in pancreatic ductal adenocarcinoma. Precise evaluation of lymph node metastasis will not only help in formulating personalized treatment but also provide more accurate prognostic information to the patients. This review aims at synthesizing current knowledge of the molecular mechanisms, treatment options, clinical implications, and evaluation techniques regarding lymph node metastasis in pancreatic cancer, hence allowing a focused perspective for clinicians and researchers in striving for more effective management strategies against lymph node metastasis of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.